DoW Toxic Exposures Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 7, 2026
- Amount
- Program total $4.5M
- Closes
- Nov 19, 2026 (in 68 days)
Similar opportunities open now
- DoW Toxic Exposures Translational Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 68 days
- DoW Toxic Exposures Investigator Initiated Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 68 days
- DoW Peer Reviewed Cancer, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 23 days
- DoW Peer Reviewed Medical, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 10 days
- DoW Autism Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 40 days
Classification and identifiers
- Solicitation number
- HT942526TERPCTA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $4.5M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, t...